Researchers have developed two new compounds that are able to inhibit SARS-CoV-2 main protease. The study reports one of the compounds is a strong drug candidate for further investigative trials in the treatment of coronavirus.
Six potential drug candidates have been identified as candidates to treat COVID-19 infections. The drugs, which have previously been subjected to clinical trials for treating a range of conditions, from arthritis to cancer, target Mpro, the main SARS-CoV-2 enzyme.
Researchers have decoded the 3-D architecture of the main SARS-CoV-2 protease. The protein is involved in the reproduction of the virus. The findings may help in the systematic development of drugs to inhibit the reproduction of the virus, potentially lowering COVID-19 infections.